Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 14 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/2/2007 First Published: 8/1/2000


1.		Phase I/II Study of EMD 121974 in Patients With Progressive or Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NABTT-9911 JHOC-NABTT-9911, NCT00006093, NABTT-9911

Last Modified: 5/14/2008 First Published: 5/28/2004


2.		Phase I/II Randomized Study of Cilengitide, Temozolomide, and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NABTT-0306 NABTT-0306, NCT00085254

Last Modified: 8/7/2006 First Published: 4/23/2004


3.		Phase II Randomized Study of Cilengitide in Patients With Unresectable Stage III or Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MDA-2003-0988 6387, NCI-6387, NCT00082875

Last Modified: 7/17/2006 First Published: 7/23/2004


4.		Phase II Randomized Study of Cilengitide as Maintenance Therapy in Patients With Acute Myeloid Leukemia in First Complete Remission

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				50 and over				NCI				MDA-2003-1007 6384, NCI-6384, NCT00089388

Last Modified: 7/6/2007 First Published: 1/24/2005


5.		Phase II Randomized Study of Cilengitide in Patients With Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CCUM-2004-030 NCI-6372, 6372, UCSF-045512, UCSF-H45860-26715-01B, NCT00103337

Last Modified: 7/18/2007 First Published: 1/24/2005


6.		Phase II Randomized Study of Cilengitide in Patients With Recurrent or Progressive Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UCLA-0408014-01 EMD-121974-009, MERCK-EMD-121974-009, NCT0093964

Last Modified: 10/10/2007 First Published: 5/23/2005


7.		Phase II Study of Cilengitide in Operative Patients With Recurrent or Progressive Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NABTC-0302 NABTC-03-02, NCT00112866

Last Modified: 2/18/2008 First Published: 7/15/2005


8.		Phase II Study of Cilengitide in Patients With Non-Metastatic Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CCUM-2004-045 6735, NCI-6735, NCT00121238


9.		Pilot hu14.18-IL2 and Cilengitide in Resectable Recurrent Stage III or Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Temporarily closed				18 and over				NCI, Other				H2007-0087 CO05601, NCT00590824

Last Modified: 5/23/2007 First Published: 2/1/2000


10.		Phase I Study of EMD 121974 in Patients With Advanced or Metastatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				IUMC-9909-40 NCI-T99-0076, NCT00004258, T99-0076

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute